ArticlePublished 30 Mar 2024
Teriflunomide for Elderly Patients with Benign MS and Cognitive Impairment: Balancing Brain Atrophy Reduction with Safety Considerations
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction This study investigates Teriflunomide's potential to mitigate brain atrophy and its impact on cognitive function in MS patients. Method The study combines a case study and a cohort study. The case involves a 60-year-old woman with MS experiencing cognitive decline despite a stable EDSS score. The cohort consisted of 46 clinically stable Multiple Sclerosis (MS) patients who received teriflunomide treatment. Brain atrophy markers and cognitive function were evaluated. Results The case study patient showed signs of cognitive decline on the SDMT. The cohort study revealed teriflunomide treatment did not affect the corpus callosum index but resulted in a significant increase in third ventricle width, a potential indicator of brain atrophy. Conclusion Teriflunomide may offer benefits in mitigating brain atrophy in MS. The study proposes using declining Symbol Digit Modalities Test (SDMT) scores to proactively identify MS progression and suggests teriflunomide as a potential treatment approach. Further research is needed to confirm the link between teriflunomide and cognitive improvement.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Multiple Sclerosis
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Priya Kumari”
- BylineArticles whose byline prints “Shivani Tomar”
